stoxline Quote Chart Rank Option Currency Glossary
Krystal Biotech, Inc. (KRYS)
209.68  1.8 (0.87%)    07-16 12:17
Open: 210
High: 214.98
Volume: 150,468
Pre. Close: 207.88
Low: 208.885
Market Cap: 5,988(M)
Technical analysis
2024-07-16 11:51:15 AM
Short term     
Mid term     
Targets 6-month :  251.09 1-year :  293.28
Resists First :  214.97 Second :  251.09
Pivot price 189.89
Supports First :  186.19 Second :  168.41
MAs MA(5) :  202.47 MA(20) :  186.17
MA(100) :  169.99 MA(250) :  137.93
MACD MACD :  8.9 Signal :  6.5
%K %D K(14,3) :  93.2 D(3) :  94
RSI RSI(14): 79.2
52-week High :  214.97 Low :  93.94
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ KRYS ] has closed below upper band by 2.5%. Bollinger Bands are 38% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 208.56 - 209.36 209.36 - 210.16
Low: 199.63 - 200.59 200.59 - 201.55
Close: 206.31 - 207.8 207.8 - 209.29
Company Description

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.

Headline News

Mon, 15 Jul 2024
Krystal Biotech (NASDAQ:KRYS) Hits New 1-Year High at $205.25 - MarketBeat

Mon, 15 Jul 2024
BNP Paribas Financial Markets Has $2.99 Million Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat

Mon, 15 Jul 2024
BNP Paribas Financial Markets Sells 22,294 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World

Sun, 14 Jul 2024
TimesSquare Capital Management LLC Sells 153,309 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - MarketBeat

Sun, 14 Jul 2024
Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by Mirae Asset Global Investments Co. Ltd. - Defense World

Sat, 13 Jul 2024
17,843 Shares in Krystal Biotech, Inc. (NASDAQ:KRYS) Acquired by Janney Montgomery Scott LLC - Defense World

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 29 (M)
Shares Float 21 (M)
Held by Insiders 12.6 (%)
Held by Institutions 94.8 (%)
Shares Short 2,900 (K)
Shares Short P.Month 2,810 (K)
Stock Financials
EPS 2.18
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 28.02
Profit Margin 59.5 %
Operating Margin 12.8 %
Return on Assets (ttm) -5 %
Return on Equity (ttm) 8.8 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 3.35
EBITDA (p.s.) -1.78
Qtrly Earnings Growth 0 %
Operating Cash Flow -47 (M)
Levered Free Cash Flow -45 (M)
Stock Valuations
PE Ratio 96.13
PEG Ratio 0
Price to Book value 7.47
Price to Sales 62.37
Price to Cash Flow -128
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android